The myelinated axon is dependent on the myelinating cell for support and maintenance: Molecules involved

Journal of Neuroscience Research

Volumn 76, Issue 5, 2004, Pages 593-598

  Edgar, J M ^a   Garbern, J ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 ,3 cyclic nucleotide 3 phosphodiesterase; Axon; Myelin; Proteolipid protein

Indexed keywords

MYELIN PROTEIN;

CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CELL STRUCTURE; GENE FUNCTION; GLIA CELL; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MULTIPLE SCLEROSIS; MYELIN DEFICIENCY; MYELIN SHEATH; MYELINATION; NERVE CELL; NERVE CONDUCTION; NERVE FIBER; NERVE FIBER DEGENERATION; NERVE FIBER MEMBRANE; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; PLP GENE; PRIORITY JOURNAL; PROTEIN TRANSPORT; SCHWANN CELL; SHORT SURVEY;

ANIMALS; AXONS; DEMYELINATING DISEASES; HUMANS; MYELIN PROTEINS; NERVE FIBERS, MYELINATED; OLIGODENDROGLIA; PROTEIN TRANSPORT; SCHWANN CELLS;

EID: 2542472379     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20063     Document Type: Short Survey

References (71)

1. Aguayo AJ, Bray GM, Perkins SC. 1979. Axon-Schwann cell relationships in neuropathies of mutant mice. Ann N Y Acad Sci 317:512-531.
2. Arroyo EJ, Xu YT, Zhou L, Messing A, Peles E, Chiu SY, Scherer SS. 1999. Myelinating Schwann cells determine the intermodal localization of Kv1.1, Kv1.2, Kvβ2, and Caspr. J Neurocytol 28:333-347.
3. + channel clustering. J Neurosci Res 58:752-764.
4. Barres BA, Barde YA. 2000. Neuronal and glial cell biology. Curr Opin Neurobiol 10:642-648.
5. Bjartmar C, Trapp BD. 2001. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14:271-278.
6. Bjartmar C, Yin XH, Trapp BD. 1999. Axonal pathology in myelin disorders. J Neurocytol 28:383-395.
7. Bjartmar C, Wujek JR, Trapp BD. 2003. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206:165-171.
8. Boison D, Stoffel W. 1994. Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice. Proc Natl Acad Sci USA 91:11709-11713.
9. Bongarzone ER, Campagnoni CW, Kampf K, Jacobs E, Handley VW, Schonmann V, Campagnoni AT. 1999. Identification of a new exon in the myelin proteolipid protein gene encoding novel protein isoforms that are restricted to the somata of oligodendrocytes and neurons. J Neurosci 19:8349-8357.
10. Boucher SEM, Cypher MA, Carlock LR, Skoff RP. 2002. Proteolipid protein gene modulates viability and phenotype of neurons. J Neurosci 22:1772-1783.
11. Brady ST, Witt AS, Kirkpatrick LL, De Waegh SM, Readhead C, Tu PH, Lee VMY. 1999. Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 19:7278-7288.
12. Braun PE, Sandillon F, Edwards A, Matthieu J-M, Privat A. 1988. Immunocytochemical localization by electron microscopy of 2′ 3′-cyclic nucleotide 3′-phosphodiesterase in developing oligodendrocytes of normal and mutant brain. J Neurosci 8:3057-3066.
13. Braun PE, De Angelis D, Shtybel WW, Bernier L. 1991. Isoprenoid modification permits 2′ 3′-cyclic nucleotide 3′ -phosphodiesterase to bind to membranes. J Neurosci Res 30:540-544.
14. Chance PF, Fischbeck KH. 1994. Molecular genetics of Charcot-Marie-Tooth disease and related neuropathies. Hum Mol Genet 3:1503-1507.
15. Compston A, Coles A. 2002. Multiple sclerosis. Lancet 359:1221-1231.
16. Dashiell SM, Tanner SL, Pant HC, Quarles RH. 2002. Myelin-associated glycoprotein modulates expression and phosphorylation of neuronal cytoskeletal elements and their associated kinases. J Neurochem 81:1263-1272.
17. De Angelis DA, Braun PE. 1994. Isoprenylation of brain 2′ 3′-cyclic nucleotide 3′-phosphodiesterase modulates cell morphology. J Neurosci Res 39:386-397.
18. De Stefano N, Matthews PM, Narayanan S, Francis GS, Antel JP, Arnold DL. 1997. Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 49:1138-1141.
19. De Stefano N, Matthews PM, Fu LQ, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL. 1998. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis-results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469-1477.
20. De Waegh SM, Brady ST. 1990. Altered slow axonal transport and regeneration in a myelin-deficient mutant mouse: the trembler as an in vivo model for Schwann cell-axon interactions. J Neurosci 10:1855-1865.
21. De Waegh SM, Lee VMY, Brady ST. 1992. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 68:451-463.
22. Domeniconi M, Cao ZU, Spencer T, Sivasankaran R, Wang KC, Nikulina E, Kimura N, Cai H, Deng KW, Gao Y, He ZG, Filbin MT. 2002. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 35:283-290.
23. Dyck PJ, Karnes JL, Lambert EH. 1989. Longitudinal study of neuropathic deficits and nerve conduction abnormalities in hereditary motor and sensory neuropathy type 1. Neurology 39:1302-1308.
24. Dyer CA. 2002. The structure and function of myelin: from inert membrane to perfusion pump. Neurochem Res 27:1279-1292.
25. Edgar JM, McLaughlin M, Zhang SC, McCulloch MC, Barrie JA, Duncan ID, Nave K-A, Griffiths IR. 2001. Proteolipid protein deficient myelin induces axonal swellings in shiverer mice. Soc Neurosci Abstr 103:11.
26. Franzen R, Tanner SL, Dashiell SM, Rottkamp CA, Hammer JA, Quarles RH. 2001. Microtubule-associated protein 1B: a neuronal binding partner for myelin-associated glycoprotein. J Cell Biol 155:893-898.
27. Fruttiger M, Montag D, Schachner M, Martini R. 1995. Crucial role for the myelin-associated glycoprotein in the maintenance of axon-myelin integrity. Eur J Neurosci 7:511-515.
28. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL. 1998. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121:103-113.
29. Garbern J, Yool DA, Moore GJ, Wilds I, Faulk M, Klugmann M, Nave K-A, Sistermans EA, van der Knaap MS, Bird TD, Shy ME, Kamholz J, Griffiths IR. 2002. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 125:551-561.
30. 0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 71:565-576.
31. Girault JA, Peles E. 2002. Development of nodes of Ranvier. Curr Opin Neurobiol 12:476-485.
32. Griffiths IR, Klugmann M, Anderson TJ, Yool D, Thomson CE, Schwab MH, Schneider A, Zimmermann F, McCulloch MC, Nadon NL, Nave K-A. 1998. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280:1610-1613.
33. Hodes ME, Blank CA, Pratt VM, Morales J, Napier J, Dlouhy SR. 1997. Nonsense mutation in exon 3 of the proteolipid protein gene (PLP) in a family with an unusual form of Pelizaeus-Merzbacher disease. Am J Med Genet 69:121-125.
34. Ishibashi T, Dupree JL, Ikenaka K, Hirahara Y, Honke K, Peles E, Popko B, Suzuki K, Nishino H, Baba H. 2002. A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J Neurosci 22:6507-6514.
35. Joe E, Angelides K. 1992. Clustering of voltage-dependent sodium channels on axons depends on Schwann cell contact. Nature 356:333-335.
36. Kamholz J, Menichella D, Jani A, Garbern J, Lewis RA, Krajewski KM, Lilien J, Scherer SS, Shy ME. 2000. Charcot-Marie-Tooth disease type 1-molecular pathogenesis to gene therapy. Brain 123:222-233.
37. Kaplan MR, Meyer-Franke A, Lamber S, Bennett V, Duncan ID, Levinson SR, Barres BA. 1997. Induction of sodium channel clustering by oligodendrocytes. Nature 386:724-728.
38. Kirkpatrick LL, Witt AS, Payne HR, Shine HD, Brady ST. 2001. Changes in microtubule stability and density in myelin-deficient shiverer mouse CNS axons. J Neurosci 21:2288-2297.
39. Klugmann M, Schwab MH, Pühlhofer A, Schneider A, Zimmermann F, Griffiths IR, Nave K-A. 1997. Assembly of CNS myelin in the absence of proteolipid protein. Neuron 18:59-70.
40. Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J, Kamholz J, Shy ME. 2000. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 123:1516-1527.
41. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave K-A. 2003. Disruption of the CNP gene uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 33:366-374.
42. Menon K, Rasband MN, Taylor CM, Brophy P, Bansal R, Pfeiffer SE. 2003. The myelin-axolemmal complex: biochemical dissection and the role of galactosphingolipids. J Neurochem 87:995-1009.
43. Murakami T, Garcia CA, Reiter LT, Lupski JR. 1996. Charcot-Marie-Tooth disease and related inherited neuropathies. Medicine 75:233-250.
44. Narayanan S, Fu L, Pioro E, De Stefano N, Collins DL, Francis GS, Antel JP, Matthews PM, Arnold DL. 1997. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 41:385-391.
45. Nishizawa Y, Kurihara T, Masuda T, Takahashi Y. 1985. Immunohistochemical localization of 2′ 3′-cyclic nucleotide 3′-phosphodiesterase in adult bovine cerebrum and cerebellum. Neurochem Res 8:1107-1118.
46. Novotny GE. 1984. Formation of cytoplasm-containing vesicles from double-walled coated invaginations containing oligodendrocytic cytoplasm at the axon-myelin sheath interface in adult mammalian central nervous system. Acta Anat 119:106-112.
47. Osaka H, Kawanishi C, Inoue K, Uesugi H, Hiroshi K, Nishiyama K, Yamada Y, Suzuki K, Kimura S, Kosaka K. 1995. Novel nonsense proteolipid protein gene mutation as a cause of X-linked spastic paraplegia in twin males. Biochem Biophys Res Commun 215:835-841.
48. Peles E, Salzer JL. 2000. Molecular domains of myelinated axons. Curr Opin Neurobiol 10:558-565.
49. Poliak S, Peles E. 2003. The local differentiation of myelinated axons at nodes of Ranvier. Nat Rev Neurosci 4:968-980.
50. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH, Ludlow CL, Fischbeck KH. 2003. Mutant dynactin in motor neuron disease. Nat Genet 33:455-456.
51. Rasband MN, Peles E, Trimmer JS, Levinson SR, Lux SE, Shrager P. 1999. Dependence of nodal sodium channel clustering on paranodal axoglial contact in the developing CNS. J Neurosci 19:7516-7528.
52. Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA, Rubinsztein DC, Marchuk DA. 2002. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 71:1189-1194.
53. Rudick RA, Goodman A, Herndon RM, Panitch HS. 1999. Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment. J Neuroimmunol 98:22-28.
54. Sahenk Z, Chen L. 1998. Abnormalities in the axonal cytoskeleton induced by a connexin32 mutation in nerve xenografts. J Neurosci Res 51:174-184.
55. Sahenk Z, Chen L, Mendell JR. 1999. Effects of PMP22 duplication and deletions on the axonal cytoskeleton. Ann Neurol 45:16-24.
56. Salzer JL. 2003. Polarized domains of myelinated axons. Neuron 40:297-318.
57. Salzer JL, Holmes WP, Colman DR. 1987. The amino acid sequence of the myelin-associated glycoproteins: homology to the immunoglobulin gene superfamily. J Cell Biol 104:957-965.
58. Sánchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA. 1996. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 16:5095-5105.
59. Scolding N, Franklin R. 1998. Axon loss in multiple sclerosis. Lancet 352:340-341.
60. Shy ME, Hobson G, Jain M, Boespflug-Tanguy O, Garbern J, Sperle K, Li W, Gow A, Rodriguez D, Bertini E, Mancias P, Krajewski K, Lewis R, Kamholz J. 2003. Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol 53:354-365.
61. Snipes GJ, Suter U. 1995. Molecular basis of common hereditary motor and sensory neuropathies in humans and in mouse models. Brain Pathol 5:233-247.
62. Spörkel O, Uschkureit T, Büssow H, Stoffel W. 2002. Oligodendrocytes expressing exclusively the DM20 isoform of the proteolipid protein gene: myelination and development. Glia 37:19-30.
63. Stecca B, Southwood CM, Gragerov A, Kelley KA, Friedrich VL Jr, Gow A. 2000. The evolution of lipophilin genes from invertebrates to tetrapods: DM-20 cannot replace proteolipid protein in CNS myelin. J Neurosci 20:4002-4010.
64. Sternberger NH, Quarles RH, Itoyama Y, Webster HD. 1979. Myelin-associated glycoprotein demonstrated immunocytochemically in myelin and myelin-forming cells of developing rat. Proc Natl Acad Sci USA 76:1510-1514.
65. Trapp BD, Bernier L, Andrews B, Colman DR. 1988. Cellular and subcellular distribution of 2′ 3′-cyclic nucleotide 3′-phosphodiesterase and its mRNA in the rat central nervous system. J Neurochem 51:859-868.
66. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285.
67. Uschkureit T, Spörkel O, Stracke J, Büssow H, Stoffel W. 2000. Early onset of axonal degeneration in double (plp-/-mag-/-) and hypomyelinosis in triple (plp-/-mbp-/-mag-/-) mutant mice. J Neurosci 20:5225-5233.
68. Vyas AA, Patel HV, Fromholt SE, Heffer-Lauc M, Vyas KA, Dang JY, Schachner M, Schnaar RL. 2002. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci USA 99:8412-8417.
69. Witt A, Brady ST. 2000. Unwrapping new layers of complexity in axon/ glial relationships. Glia 29:112-117.
70. Yin XH, Crawford TO, Griffin JW, Tu PH, Lee VM, Li CM, Roder J, Trapp BD. 1998. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 18:1953-1962.
71. Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, Takeda S, Yang HW, Terada S, Nakata T, Takei Y, Saito M, Tsuji S, Hayashi Y, Hirokawa N. 2001. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bβ. Cell 105:587-597.